The Punjab Drug Regulatory Authority has issued a medical product alert regarding seven medicines, including antibiotics and anti-allergic drugs, that fail to meet quality standards.
The Punjab Drug Testing Laboratory confirmed that these medicines are substandard, prompting urgent regulatory action. The affected drugs did not meet ASSA test standards and were found to contain foreign particles and adulteration.
Manufactured by pharmaceutical companies in Lahore and Rawalpindi, the substandard medicines include three batches of Methylcobalamin injections and tablets, one batch of anti-allergic medication, and two batches of antibiotics.
Specific medicines flagged include:
Neocobal Injection (Batch S-2455)
Meclomine Tablets (Batches 8440, 8482)
Amekoran Injection (Batch BK-019)
Aqua-P Sterile Water (Batch 669)
Ortizin Tablets (Batch 241268)
Dorcip Antibiotic Drip (Batch DC-121)
The Punjab Drug Regulatory Authority has urged the Punjab government to take immediate action to prevent the distribution of these flagged medicines. Enhanced market surveillance and thorough inspections of the supply chain are underway.
The sale of these medicines has been strictly halted for pharmacies and distributors, who are required to report any suspicious lots. The public is advised to be vigilant as the use of these substandard medicines can adversely affect treatment outcomes.
Earlier, the Drug Regulatory Authority of Pakistan (DRAP) launched a nationwide campaign against the illegal sale, manufacturing, and distribution of counterfeit medicines. In Lahore, DRAP apprehended individuals selling unlicensed Urografin 76% Injection and unregistered Lipiodol Ultra Liquid, seized illicit articles, and initiated formal investigations. Additionally, DRAP took action against the illegal manufacturing of unregistered medical devices, seizing the devices and sealing the facility.
